TC BioPharm Announces Dr. Mike Leek as Chief Technology Officer

Rhea-AI Summary

TC BioPharm (NASDAQ: TCBP) has appointed Dr. Michael Leek as Chief Technology Officer, resuming operational duties after previously serving as Executive Chairman since June 2021. With over 35 years in cell-based R&D, Dr. Leek co-founded the company in July 2013 and has extensive experience in clinical development. He aims to drive innovation in gamma-delta T cell therapies for cancer treatment, reporting to CEO Bryan Kobel. TCBP leads in developing these therapies and is conducting pivotal clinical trials for its OmnImmune® product in acute myeloid leukemia, utilizing proprietary allogeneic CryoTC technology to supply clinics globally.

Positive

• Dr. Michael Leek's extensive experience (35+ years) in cell-based R&D strengthens TCBP's leadership.
• The company is a leader in gamma-delta T cell therapy development, positioning itself well in the oncology market.
• Conducting two pivotal clinical trials, including Phase 2b/3 for OmnImmune® in treating acute myeloid leukemia.

Negative

• None.

News Market Reaction – TCBP

-11.13%

-11.13% Session move

In the trading session that priced this news, TCBP declined 11.13%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

EDINBURGH, Scotland, Feb. 23, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the appointment of Dr. Michael Leek to the position of Chief Technology Officer. Dr. Leek resumes operational duties as CTO after stepping down as executive chairman of the board.

With more than 35 years experience in cell-based research and development, Co-founder, Michael Leek, Ph.D., had previously served as TC BioPharm's Executive Chairman of the board since June 2021. Prior he served as Chief Executive of TC BioPharm since founding the Company in July 2013. He has served in senior management and board roles with, Intercytex plc, a cell therapy company he co-founded. While at Intercytex, Dr. Leek was involved in clinical development of cell therapies to treat chronic dermal wounds. Early in his career, he held roles of increasing responsibility at Smith and Nephew from 1989 to 1999 as leader of the Tissue Repair Enabling Technology team. Dr. Leek holds a Ph.D. (Forensic Medicine) from the University of Leeds. He has acted as an honorary lecturer at the School of Medical Sciences, University of Aberdeen since January 2014.

"I am excited to rejoin the TC BioPharm operational team and help drive the company's technology forward," said Leek. "I look forward to working with Bryan, the executive team and the board to continue the Company's trajectory as leader in the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer and other severe diseases."

"We welcome Dr. Leek back to TC BioPharm's C-Suite in this new role," said Bryan Kobel, Chief Executive Officer. "His contributions to TC Biopharm since inception have been invaluable and I'm appreciative of Mike's strong desire to be more involved on a day-to-day basis. The innovation task force we created several months ago will report to Dr. Leek and together they've already made great strides in reviewing potential combination therapies and new opportunities for TCBP and I expect the team to continue to excel going forward."

About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue. TC BioPharm uses an allogeneic approach in both unmodified and CAR modified gamma-delta T cells to effectively identify, target and eradicate both liquid and solid tumors in cancer.

TC BioPharm is the leader in developing gamma-delta T cell therapies, and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial for OmnImmune® in treatment of acute myeloid leukemia using the Company's proprietary allogenic CryoTC technology to provide frozen product to clinics worldwide. TC BioPharm also maintains a robust pipeline for future indications in solid tumors as well as a significant IP/patent portfolio in the use of CARs with gamma-delta T cells and owns our manufacturing facility to maintain cost and product quality controls.

Forward Looking Statements

This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect our current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. We undertake no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise. The reference to the website of TC BioPharm has been provided as a convenience, and the information contained on such website is not incorporated by reference into this press release.

View original content to download multimedia:https://www.prnewswire.com/news-releases/tc-biopharm-announces-dr-mike-leek-as-chief-technology-officer-301753291.html

SOURCE TC BioPharm

FAQ

What recent leadership change occurred at TC BioPharm (TCBP)?

Dr. Michael Leek has been appointed Chief Technology Officer at TC BioPharm on February 23, 2023.

What is Dr. Michael Leek's role at TC BioPharm (TCBP) now?

He will lead the company's technology initiatives and innovation task force focusing on gamma-delta T cell therapies.

What clinical trials is TC BioPharm (TCBP) currently conducting?

TC BioPharm is conducting pivotal clinical trials for its OmnImmune® therapy for acute myeloid leukemia.

When was TC BioPharm (TCBP) founded?

TC BioPharm was founded in July 2013.